NCT05007769

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators hypothesize that the addition of ramucirumab and N-803 will augment the clinical activity of atezolizumab, and in order to evaluate the exact mechanism of action of the combination, the investigators propose a comprehensive analysis of paired peripheral blood samples collected during this study.

Conditions

• Non-small Cell Lung Cancer
• Non-small Cell Carcinoma
• NSCLC
• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Ramucirumab	Will be supplied by Lilly Oncology, free of charge to the participant
DRUG	Atezolizumab	Atezolizumab will be commercially available.
DRUG	N-803	Will be supplied free of charge to the participants by ImmunityBio

Timeline

• Start date: 2021-10-31
• Primary completion: 2024-04-30
• Completion: 2026-04-30
• First posted: 2021-08-16
• Last updated: 2021-11-05

Regulatory

• FDA-regulated drug study